Joseph Itskovitz-Eldor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Joseph Itskovitz-Eldor has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
Michal Amit
Technion
8 shared publicationsBettina Fishman
Stem Cell Therapeutics Ltd, Jerusalem, Israel
6 shared publications- Michal Amit
Technion – Israel Insitute of Technology
6 shared publications Hanna Segev
Stem Cell Center, Faculty of Medicine, Technion, Haifa, Israel
5 shared publicationsSharon Gerecht‐Nir
Department of Obstetrics and Gynecology, Rambam Medical Center, Haifa, Israel
5 shared publicationsAnna Ziskind
4 shared publications
Latest Publications
- Open Access
- 29 September 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (19) , 7215
Cardiac Fibroblast-Induced Pluripotent Stem Cell-Derived Exosomes as a Potential Therapeutic Mean for Heart Failure
The limited regenerative capacity of the injured myocardium leads to remodeling and often heart failure. Novel therapeutic approaches are essential. Induced pluripotent stem cells (iPSC) differentiated into cardiomyocytes are a potential future therapeutics. We hypothesized that organ-specific reprogramed fibroblasts may serve an advantageous source for future cardiomyocytes. Moreover, exosomes secreted from those cells may have a beneficial effect on cardiac differentiation and/or function. We compared RNA from different sources of human iPSC using chip gene expression. Protein expression was evaluated as well as exosome micro-RNA levels and their impact on embryoid bodies (EBs) differentiation. Statistical analysis identified 51 genes that were altered (p ≤ 0.05), and confirmed in the protein level, cardiac fibroblasts-iPSCs (CF-iPSCs) vs. dermal fibroblasts-iPSCs (DF-iPSCs). Several miRs were altered especially miR22, a key regulator of cardiac hypertrophy and remodeling. Lower expression of miR22 in CF-iPSCs vs. DF-iPSCs was observed. EBs treated with these exosomes exhibited more beating EBs p = 0.05. vs. control. We identify CF-iPSC and its exosomes as a potential source for cardiac recovery induction. The decrease in miR22 level points out that our CF-iPSC-exosomes are naïve of congestive heart cell memory, making them a potential biological source for future therapy for the injured heart.
- 29 September 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (19) , 7215
Open AccessCardiac Fibroblast-Induced Pluripotent Stem Cell-Derived Exosomes as a Potential Therapeutic Mean for Heart Failure
The limited regenerative capacity of the injured myocardium leads to remodeling and often heart failure. Novel therapeutic approaches are essential. Induced pluripotent stem cells (iPSC) differentiated into cardiomyocytes are a potential future therapeutics. We hypothesized that organ-specific reprogramed fibroblasts may serve an advantageous source for future cardiomyocytes. Moreover, exosomes secreted from those cells may have a beneficial effect on cardiac differentiation and/or function. We compared RNA from different sources of human iPSC using chip gene expression. Protein expression was evaluated as well as exosome micro-RNA levels and their impact on embryoid bodies (EBs) differentiation. Statistical analysis identified 51 genes that were altered (p ≤ 0.05), and confirmed in the protein level, cardiac fibroblasts-iPSCs (CF-iPSCs) vs. dermal fibroblasts-iPSCs (DF-iPSCs). Several miRs were altered especially miR22, a key regulator of cardiac hypertrophy and remodeling. Lower expression of miR22 in CF-iPSCs vs. DF-iPSCs was observed. EBs treated with these exosomes exhibited more beating EBs p = 0.05. vs. control. We identify CF-iPSC and its exosomes as a potential source for cardiac recovery induction. The decrease in miR22 level points out that our CF-iPSC-exosomes are naïve of congestive heart cell memory, making them a potential biological source for future therapy for the injured heart.
- Open Access
- 1 May 2018
- Published by Elsevier in Stem Cell Reports
- Vol. 10 (5) , 1439-1441
20th Anniversary of Isolation of Human Embryonic Stem Cells: A Personal Perspective
- 1 May 2018
- Published by Elsevier in Stem Cell Reports
- Vol. 10 (5) , 1439-1441
Open Access20th Anniversary of Isolation of Human Embryonic Stem Cells: A Personal Perspective
- 17 May 2012
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 8 (3) , 792-802
Targeting Pancreatic Progenitor Cells in Human Embryonic Stem Cell Differentiation for the Identification of Novel Cell Surface Markers
New sources of beta cells are needed in order to develop cell therapies for patients with diabetes. An alternative to forced expansion of post-mitotic beta cells is the induction of differentiation of stem-cell derived progenitor cells that have a natural self-expansion capacity into insulin-producing cells. In order to learn more about these progenitor cells at different stages along the differentiation process in which they become progressively more committed to the final beta cell fate, we took the approach of identifying, isolating and characterizing stage specific progenitor cells. We generated human embryonic stem cell (HESC) clones harboring BAC GFP reporter constructs of SOX17, a definitive endoderm marker, and PDX1, a pancreatic marker, and identified subpopulations of GFP expressing cells. Using this approach, we isolated a highly enriched population of pancreatic progenitor cells from hESCs and examined their gene expression with an emphasis on the expression of stage-specific cell surface markers. We were able to identify novel molecules that are involved in the pancreatic differentiation process, as well as stage-specific cell markers that may serve to define (alone or in combination with other markers) a specific pancreatic progenitor cell. These findings may help in optimizing conditions for ultimately generating and isolating beta cells for transplantation therapy.
- 17 May 2012
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 8 (3) , 792-802
Targeting Pancreatic Progenitor Cells in Human Embryonic Stem Cell Differentiation for the Identification of Novel Cell Surface Markers
New sources of beta cells are needed in order to develop cell therapies for patients with diabetes. An alternative to forced expansion of post-mitotic beta cells is the induction of differentiation of stem-cell derived progenitor cells that have a natural self-expansion capacity into insulin-producing cells. In order to learn more about these progenitor cells at different stages along the differentiation process in which they become progressively more committed to the final beta cell fate, we took the approach of identifying, isolating and characterizing stage specific progenitor cells. We generated human embryonic stem cell (HESC) clones harboring BAC GFP reporter constructs of SOX17, a definitive endoderm marker, and PDX1, a pancreatic marker, and identified subpopulations of GFP expressing cells. Using this approach, we isolated a highly enriched population of pancreatic progenitor cells from hESCs and examined their gene expression with an emphasis on the expression of stage-specific cell surface markers. We were able to identify novel molecules that are involved in the pancreatic differentiation process, as well as stage-specific cell markers that may serve to define (alone or in combination with other markers) a specific pancreatic progenitor cell. These findings may help in optimizing conditions for ultimately generating and isolating beta cells for transplantation therapy.
- 6 January 2012
- Published by SAGE Publications in Stem Cells and Development
- Vol. 21 (10) , 1653-1661
The Expression of the Class 1 Glucose Transporter Isoforms in Human Embryonic Stem Cells, and the Potential Use of GLUT2 as a Marker for Pancreatic Progenitor Enrichment
Even before the first appearance of the developing pancreas, glucose is the major substrate in the growing embryo. The transport of glucose across cell membranes is facilitated by a family of membranal glucose transporters (GLUT). We analyzed changes in expression of class 1 glucose transporters (GLUT1–4) during human embryonic stem cell (hESC) and human induced pluripotent stem cell (hiPSC) differentiation, from undifferentiated cells to 28-day-old embryoid bodies (EBs). We also examined the potential use of GLUT2 as a marker for differentiating pancreatic progenitor cells. Using quantitative real time polymerase chain reaction (qPCR), western blot, and immunofluorescence, we observed enhanced expression of GLUT1 and GLUT2 during differentiation, but only minor change in GLUT3 expression. GLUT4 expression was found to be very low both at the RNA and in the protein levels. Expression of the early pancreatic transcription factor, pancreatic duodenal homeobox gene 1 (PDX1), correlated with GLUT2 expression, suggesting the potential use of GLUT2 as a surface marker for tracking pancreatic precursor cells. After sorting EBs according to their membranal GLUT2 expression, GLUT2 and PDX1 expression were found elevated, as was expression of other endodermal markers such as PAX4, NGN3, CXCR4, and SOX17. This simple method may be used to differentiate embryonic stem cells and to isolate from them, using GLUT2 as a surface marker, an enriched pancreatic progenitor cell population in order to achieve insulin-producing cells. The sorted GLUT2 cells may potentially be used in the future as insulin-producing cells for beta cell therapies.
- 6 January 2012
- Published by SAGE Publications in Stem Cells and Development
- Vol. 21 (10) , 1653-1661
The Expression of the Class 1 Glucose Transporter Isoforms in Human Embryonic Stem Cells, and the Potential Use of GLUT2 as a Marker for Pancreatic Progenitor Enrichment
Even before the first appearance of the developing pancreas, glucose is the major substrate in the growing embryo. The transport of glucose across cell membranes is facilitated by a family of membranal glucose transporters (GLUT). We analyzed changes in expression of class 1 glucose transporters (GLUT1–4) during human embryonic stem cell (hESC) and human induced pluripotent stem cell (hiPSC) differentiation, from undifferentiated cells to 28-day-old embryoid bodies (EBs). We also examined the potential use of GLUT2 as a marker for differentiating pancreatic progenitor cells. Using quantitative real time polymerase chain reaction (qPCR), western blot, and immunofluorescence, we observed enhanced expression of GLUT1 and GLUT2 during differentiation, but only minor change in GLUT3 expression. GLUT4 expression was found to be very low both at the RNA and in the protein levels. Expression of the early pancreatic transcription factor, pancreatic duodenal homeobox gene 1 (PDX1), correlated with GLUT2 expression, suggesting the potential use of GLUT2 as a surface marker for tracking pancreatic precursor cells. After sorting EBs according to their membranal GLUT2 expression, GLUT2 and PDX1 expression were found elevated, as was expression of other endodermal markers such as PAX4, NGN3, CXCR4, and SOX17. This simple method may be used to differentiate embryonic stem cells and to isolate from them, using GLUT2 as a surface marker, an enriched pancreatic progenitor cell population in order to achieve insulin-producing cells. The sorted GLUT2 cells may potentially be used in the future as insulin-producing cells for beta cell therapies.
- Open Access
- 2 November 2011
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 16 (3) , 468-482
Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to β‐adrenergic stimulation
Sudden cardiac death caused by ventricular arrhythmias is a disastrous event, especially when it occurs in young individuals. Among the five major arrhythmogenic disorders occurring in the absence of a structural heart disease is catecholaminergic polymorphic ventricular tachycardia (CPVT), which is a highly lethal form of inherited arrhythmias. Our study focuses on the autosomal recessive form of the disease caused by the missense mutation D307H in the cardiac calsequestrin gene, CASQ2. Because CASQ2 is a key player in excitation contraction coupling, the derangements in intracellular Ca2+ handling may cause delayed afterdepolarizations (DADs), which constitute the mechanism underlying CPVT. To investigate catecholamine‐induced arrhythmias in the CASQ2 mutated cells, we generated for the first time CPVT‐derived induced pluripotent stem cells (iPSCs) by reprogramming fibroblasts from skin biopsies of two patients, and demonstrated that the iPSCs carry the CASQ2 mutation. Next, iPSCs were differentiated to cardiomyocytes (iPSCs‐CMs), which expressed the mutant CASQ2 protein. The major findings were that the β‐adrenergic agonist isoproterenol caused in CPVT iPSCs‐CMs (but not in the control cardiomyocytes) DADs, oscillatory arrhythmic prepotentials, after‐contractions and diastolic [Ca2+]i rise. Electron microscopy analysis revealed that compared with control iPSCs‐CMs, CPVT iPSCs‐CMs displayed a more immature phenotype with less organized myofibrils, enlarged sarcoplasmic reticulum cisternae and reduced number of caveolae. In summary, our results demonstrate that the patient‐specific mutated cardiomyocytes can be used to study the electrophysiological mechanisms underlying CPVT.
- 2 November 2011
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 16 (3) , 468-482
Open AccessCardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to β‐adrenergic stimulation
Sudden cardiac death caused by ventricular arrhythmias is a disastrous event, especially when it occurs in young individuals. Among the five major arrhythmogenic disorders occurring in the absence of a structural heart disease is catecholaminergic polymorphic ventricular tachycardia (CPVT), which is a highly lethal form of inherited arrhythmias. Our study focuses on the autosomal recessive form of the disease caused by the missense mutation D307H in the cardiac calsequestrin gene, CASQ2. Because CASQ2 is a key player in excitation contraction coupling, the derangements in intracellular Ca2+ handling may cause delayed afterdepolarizations (DADs), which constitute the mechanism underlying CPVT. To investigate catecholamine‐induced arrhythmias in the CASQ2 mutated cells, we generated for the first time CPVT‐derived induced pluripotent stem cells (iPSCs) by reprogramming fibroblasts from skin biopsies of two patients, and demonstrated that the iPSCs carry the CASQ2 mutation. Next, iPSCs were differentiated to cardiomyocytes (iPSCs‐CMs), which expressed the mutant CASQ2 protein. The major findings were that the β‐adrenergic agonist isoproterenol caused in CPVT iPSCs‐CMs (but not in the control cardiomyocytes) DADs, oscillatory arrhythmic prepotentials, after‐contractions and diastolic [Ca2+]i rise. Electron microscopy analysis revealed that compared with control iPSCs‐CMs, CPVT iPSCs‐CMs displayed a more immature phenotype with less organized myofibrils, enlarged sarcoplasmic reticulum cisternae and reduced number of caveolae. In summary, our results demonstrate that the patient‐specific mutated cardiomyocytes can be used to study the electrophysiological mechanisms underlying CPVT.
- 25 October 2011
- Published by Springer Nature
- p. 91-103
Differentiation of Pluripotent Stem Cells In Vivo: Teratoma Formation
- 25 October 2011
- Published by Springer Nature
- p. 91-103
Differentiation of Pluripotent Stem Cells In Vivo: Teratoma Formation
- 25 October 2011
- Published by Springer Nature
- p. 73-89
Differentiation of Pluripotent Stem Cells In Vitro: Embryoid Bodies
- 25 October 2011
- Published by Springer Nature
- p. 73-89
Differentiation of Pluripotent Stem Cells In Vitro: Embryoid Bodies
- 25 October 2011
- Published by Springer Nature
- p. 57-72
Morphology of Undifferentiated Human Embryonic and Induced Stem Cells Grown in Suspension and in Dynamic Cultures
- 25 October 2011
- Published by Springer Nature
- p. 57-72
Morphology of Undifferentiated Human Embryonic and Induced Stem Cells Grown in Suspension and in Dynamic Cultures
- 25 October 2011
- Published by Springer Nature
- p. 41-55
Morphology of Human Embryonic Stem Cells and Induced Pluripotent Stem Cells Cultured in Feeder Layer-Free Conditions
- 25 October 2011
- Published by Springer Nature
- p. 41-55
Morphology of Human Embryonic Stem Cells and Induced Pluripotent Stem Cells Cultured in Feeder Layer-Free Conditions
- 25 October 2011
- Published by Springer Nature
- p. 15-39
Morphology of Human Embryonic and Induced Pluripotent Stem Cell Colonies Cultured with Feeders
- 25 October 2011
- Published by Springer Nature
- p. 15-39
Morphology of Human Embryonic and Induced Pluripotent Stem Cell Colonies Cultured with Feeders